UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report
(Date of earliest event reported): December 3, 2018
TG Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th
Floor
New York, New York 10014
(Address of
Principal Executive Offices)
(212) 554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities
Act.
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.
☐
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On December 3,
2018, TG Therapeutics, Inc. (the “Company”) issued a
press release announcing updated clinical data from its Phase I/II
trial of ublituximab (TG-1101), the Company’s novel
glycoengineered anti-CD20 monoclonal antibody in combination with
umbralisib (TGR-1202), the Company’s oral, next generation
PI3K delta inhibitor, and pembrolizumab, in patients with
relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and
Richter’s Transformation (RT) presented during the
60th
American Society of Hematology (ASH) Annual Meeting and Exposition.
On December 4, 2018 the Company also announced updated clinical
data from its Phase I/Ib trial of ublituximab in combination with
umbralisib, and bendamustine, in patients with Diffuse Large B-cell
Lymphoma (DLBCL) and Follicular Lymphoma (FL) also presented during
the 60th
Annual ASH Meeting. Copies of the press releases are being filed as
Exhibit 99.1 and Exhibit 99.2 and incorporated in this Item by
reference.
Item 9.01 Financial Statements And
Exhibits.
(d)
Exhibits.
99.1 Press Release, dated December 3,
2018.
99.2 Press Release, dated December 4,
2018.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
Date: December 4,
2018
|
|
|
|
By: /s/
Sean A.
Power
|
|
|
Sean A.
Power
|
|
|
Chief Financial
Officer
|
|
|
|